
  
    
      
        
        Shah_NNP Ebrahim_NNP says_VBZ ,_, in_IN his_PRP$ answer_NN to_TO my_PRP$ statement_NN in_IN our_PRP$ debate_NN [_NN 1_CD ]_NN ,_, that_DT plaque_NN is_VBZ so_RB
        common_JJ that_IN it_PRP makes_VBZ sense_NN to_TO treat_VB only_RB those_DT likely_JJ to_TO have_VB an_DT acute_JJ event_NN in_IN the_DT near_JJ
        future_NN ._. Not_RB everyone_NN has_VBZ a_DT heart_NN attack_NN but_CC everyone_NN ages_NNS ,_, nor_CC can_MD we_PRP be_VB sure_JJ who_WP will_MD be_VB
        lucky_JJ as_IN they_PRP age_VBP and_CC who_WP will_MD not_RB ._. Anyone_NN with_IN a_DT low-density_NN lipoprotein_NN level_NN above_IN 70_CD
        mg_NN /_NN dl_NN is_VBZ at_IN risk_NN [_NN 2_CD ]_NN ._. Narrowing_VBG of_IN arteries_NNS must_MD certainly_RB contribute_VB to_TO health_NN decline_NN in_IN
        aging_VBG ._. He_PRP says_VBZ that_IN most_JJS plaque_NN is_VBZ stable_JJ and_CC does_VBZ not_RB rupture_NN ._. The_DT half-million_JJ people_NNS who_WP
        have_VBP a_DT heart_NN attack_NN and_CC the_DT hundreds_NNS of_IN thousands_NNS of_IN individuals_NNS who_WP have_VBP a_DT stroke_NN in_IN the_DT
        United_NNP States_NNPS alone_RB each_DT year_NN would_MD disagree_VB ._. Waiting_NNP decades_NNS more_JJR for_IN further_JJ studies_NNS will_MD
        not_RB help_VB all_PDT those_DT now_RB succumbing_VBG to_TO the_DT disease_NN ,_, as_RB long_RB as_IN all_PDT the_DT components_NNS have_VBP
        already_RB been_VBN well_RB vetted_JJ ,_, as_IN they_PRP have_VBP been_VBN ._. Ebrahim_NNP 's_POS statement_NN that_IN “ most_JJS [_NN plaques_NNS ]_NN are_VBP
        stable_JJ and_CC unlikely_JJ to_TO rupture_NN” is_VBZ based_VBN on_IN his_PRP$ own_JJ study_NN published_VBN in_IN 
        Stroke_NNP [_NN 3_CD ]_NN ,_, but_CC the_DT paper_NN has_VBZ no_DT data_NNS relating_VBG to_TO how_WRB many_JJ patients_NNS found_VBD
        to_TO have_VB increased_VBN intima-media_JJ wall_NN thickness_NN (_( IMT_NNP )_) or_CC plaque_NN actually_RB had_VBD heart_NN attacks_NNS or_CC
        strokes_NNS ._. It_PRP did_VBD find_VB that_IN intimal-wall_JJ changes_NNS were_VBD highly_RB associated_VBN with_IN ischemic_JJ heart_NN
        disease_NN ._.
        It_PRP is_VBZ correct_JJ that_IN risk_NN factors_NNS can_MD predict_VB heart_NN disease_NN and_CC stroke_NN to_TO some_DT degree_NN ,_,
        though_IN I_PRP have_VBP many_JJ patients_NNS for_IN whom_WP that_DT approach_NN fails_VBZ while_IN IMT_NNP detects_NNS the_DT risk_NN
        otherwise_RB missed_VBD ._. However_RB ,_, risk_NN factor_NN analysis_NN is_VBZ not_RB enough_RB ._. Changes_NNS in_IN smoking_NN ,_, diet_NN ,_,
        weight_NN ,_, blood_NN pressure_NN ,_, and_CC such_JJ are_VBP all_DT targets_NNS for_IN treatment_NN ,_, but_CC how_WRB do_VBP doctors_NNS know_VBP
        whether_IN they_PRP have_VBP controlled_VBN them_PRP adequately_RB ?_. If_IN IMT_NNP increases_NNS ,_, more_JJR control_NN is_VBZ required_VBN ._.
        If_IN IMT_NNP stabilizes_VBZ or_CC reverses_VBZ a_DT little_JJ ,_, then_RB it_PRP means_VBZ that_DT control_NN is_VBZ at_IN goal_NN ._. Family_NN
        history_NN of_IN premature_JJ coronary_JJ artery_NN disease_NN is_VBZ a_DT major_JJ but_CC underused_JJ risk_NN factor_NN ._. The_DT
        causative_JJ factors_NNS have_VBP not_RB yet_RB been_VBN elucidated_JJ by_IN research_NN ,_, so_IN we_PRP do_VBP not_RB know_VB what_WP the_DT
        goals_NNS are_VBP ._. However_RB ,_, IMT_NNP provides_VBZ a_DT highly_RB satisfactory_JJ parameter_NN by_IN which_WDT to_TO judge_VB the_DT
        effectiveness_NN of_IN treatment_NN in_IN familial_NN coronary_JJ artery_NN disease_NN :_: IMT_NNP stabilization_NN and_CC
        reversal_NN are_VBP good_JJ ,_, whereas_IN progression_NN is_VBZ bad_JJ and_CC requires_VBZ more_RBR intensive_JJ measures_NNS ._.
        Epidemiology_NNP and_CC public-health_NN planning_NN correctly_RB look_VB at_IN policies_NNS to_TO apply_VB to_TO large_JJ
        populations_NNS ._. However_RB ,_, the_DT practice_NN of_IN medicine_NN is_VBZ patient_NN by_IN patient_NN ,_, accomplished_VBN in_IN the_DT
        face-to-face_JJ doctor–patient_NN relationship_NN ._. Policy_NNP can_MD be_VB useful_JJ as_IN a_DT resource_NN ,_, but_CC each_DT
        patient_NN should_MD have_VB the_DT maximum_NN individualized_JJ care_NN and_CC access_NN that_IN a_DT doctor_NN can_MD provide_VB ._.
        Patients_NNS should_MD be_VB able_JJ to_TO make_VB their_PRP$ own_JJ informed_VBN choices_NNS and_CC not_RB be_VB dictated_VBN to_TO by_IN
        policies_NNS meant_VBN for_IN masses_NNS ._. Should_MD n't_RB everyone_NN with_IN increased_VBN IMT_NNP at_IN least_JJS be_VB informed_VBN of_IN
        the_DT options_NNS available_JJ to_TO limit_VB it_PRP rather_RB than_IN waiting_VBG until_IN acute_JJ events_NNS or_CC advanced_VBD
        narrowing_VBG occur_VB ?_. It_PRP would_MD be_VB best_JJS to_TO start_VB a_DT healthy_JJ lifestyle_NN from_IN birth_NN ,_, but_CC fortunately_RB
        by_IN adulthood_NN there_EX is_VBZ still_RB time_NN to_TO make_VB an_DT enormous_JJ difference_NN in_IN practical_JJ terms_NNS if_IN we_PRP
        take_VBP action_NN at_IN the_DT stage_NN when_WRB intimal_NN widening_NN is_VBZ detectable_JJ with_IN the_DT highly_RB sensitive_JJ
        ultrasound_NN described_VBD in_IN my_PRP$ original_JJ viewpoint_NN [_NN 1_CD ]_NN ._.
      
    
  
